Abstract 39P
Background
Prostate cancer (PCa) is one of the leading malignant diseases in men worldwide. The presence of myeloid-derived suppressor cells (PMN-MDSCs) is a critical contributor to a pro-tumorigenic microenvironment in advanced disease, where the neutrophil-lymphocyte ratio (NLR) is prognostic. However, their involvement in the early stages of PCa is still unclear.
Methods
Patients affected by localized prostate cancer and undergoing radical prostatectomy at the Urology Department of the University Hospital of Padua were enrolled in the study after signing informed consent. Blood and tumor samples from 79 patients were collected and immunostained for flow cytometry analysis. Disease risk groups were assigned according to EAU guidelines. Correlation between experimental data and clinical and anatomopathological features was done by logistic regression and Sperman’s correlation.
Results
No association between neutrophil counts and NLR with oncological outcome was found in a population of 79 patients with localized prostate cancer. However, a subset of circulating immature myeloid cells was found to be associated with higher disease risk groups (OR = 1.19 CI.95 (1.02, 1.38), p-value = 0.027). Of note, primary tumor lesions did not reveal a significant enrichment of the immune infiltrate and any association with clinical scores. Further analyses on defining a new potential circulating biomarker showed encouraging results. Gene expression analyses are ongoing.
Conclusions
Localized PCa is not associated with a higher circulating number of neutrophils and higher NLR compared with healthy subjects. However, further analyses of specific myeloid cell subsets are needed.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
185P - Characterizing the metabolic reprogramming of mutant ß-catenin in hepatocellular carcinoma
Presenter: Nathalie Wong
Session: Poster Display session
Resources:
Abstract
186P - Unveil and overcome PD(L)1 antibody resistance via functional genomics and clinical derived biopsies
Presenter: BIN XIE
Session: Poster Display session
Resources:
Abstract
187P - Single-cell RNA sequencing elucidates the role of intercommunication between epithelial cells, immune cells, and fibroblasts in high-grade serous ovarian cancer
Presenter: Xiaoting Zhao
Session: Poster Display session
Resources:
Abstract
188P - Single-cell and spatial transcriptomics delineate the microstructure and immune landscape of intrahepatic cholangiocarcinoma in the leading-edge area
Presenter: Zuyin li
Session: Poster Display session
Resources:
Abstract
189P - Image-guided labeling of live cells in tertiary lymphoid structures for single-cell transcriptomics
Presenter: Mengrui Cao
Session: Poster Display session
Resources:
Abstract
190P - Ex vivo modeling of precision immuno-oncology responses in lung cancer
Presenter: Bassel Alsaed
Session: Poster Display session
Resources:
Abstract
191P - Patient-derived 3D-bioprinted tumours as a relevant and innovative tool for immunotherapeutic testing.
Presenter: Kamila Pawlicka
Session: Poster Display session
Resources:
Abstract
192P - A new neuroendocrine model and in vitro effect of melatonin and serotonin on the PD-L1 ligand and its immunomodulatory action
Presenter: Dulce Caraveo Gutiérrez
Session: Poster Display session
Resources:
Abstract
193P - Humanized mice applying CD47; Prkcd; IL2rg triple KO mice exhibit enhanced human immune cell engraftment and reduced GvHD symptoms
Presenter: Seung-Ho Heo
Session: Poster Display session
Resources:
Abstract
194P - The impact of BTK inhibitors on ?d T cell fitness: Lesson for immunotherapy
Presenter: Adam Michalski
Session: Poster Display session
Resources:
Abstract